letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...7374757677787980818283...100101»
  • ||||||||||  samotolisib (LY3023414) / Eli Lilly
    Enrollment closed, Metastases:  A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) -  Jun 7, 2019   
    P1,  N=156, Active, not recruiting, 
    Recruiting --> Active, not recruiting
  • ||||||||||  letrozole / generics
    Review, Journal:  Letrozole pre-treatment prior to medical termination of pregnancy: a systematic review. (Pubmed Central) -  Jun 5, 2019   
    Recruiting --> Active, not recruiting This systematic review demonstrated that a combination of letrozole and misoprostol increased the rate of complete abortion compared to misoprostol alone in some studies, but not in others; additional well designed RCT's are needed.
  • ||||||||||  letrozole / generics
    Review, Journal:  Neuroestradiol in regulation of GnRH release. (Pubmed Central) -  Jun 4, 2019   
    Results indicate that letrozole treatment greatly attenuated the EB-induced GnRH and LH surges. Collectively, neuroestradiol released from the hypothalamus appears to be necessary for the positive feedback effect of Eon the GnRH/LH surge.
  • ||||||||||  Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap
    So, Zoladex and Letrozole? (Twitter) -  Jun 3, 2019   
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
    Enrollment open, Combination therapy, Metastases:  Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) -  May 31, 2019   
    P1/2,  N=25, Recruiting, 
    Collectively, neuroestradiol released from the hypothalamus appears to be necessary for the positive feedback effect of Eon the GnRH/LH surge. Active, not recruiting --> Recruiting
  • ||||||||||  letrozole / generics, lithium / generics
    Preclinical, Journal:  Exposure of Hyperandrogen During Pregnancy Causes Depression- and Anxiety-Like Behaviors, and Reduced Hippocampal Neurogenesis in Rat Offspring. (Pubmed Central) -  May 30, 2019   
    The lithium chloride (LICl) was used as an intervention agent since a previous study has shown that lithium chloride could promote neurogenesis in the hippocampus...Furthermore, the Wnt/β-catenin signaling pathway related to normal development of hippocampus was examined but there was no significant changes in Wnt signaling pathway members. Our study provides evidence that exposure of androgen during pregnancy leads to alterations in depressive, anxious and stereotypical behaviors and these phenotypes are possibly associated with changes in neurogenesis in the dentate gyrus.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) -  May 30, 2019   
    P2,  N=48, Active, not recruiting, 
    Our study provides evidence that exposure of androgen during pregnancy leads to alterations in depressive, anxious and stereotypical behaviors and these phenotypes are possibly associated with changes in neurogenesis in the dentate gyrus. Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring
    Trial completion:  TRial on the Endocrine Activity of Neoadjuvant Degarelix (clinicaltrials.gov) -  May 29, 2019   
    P2,  N=51, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019 Active, not recruiting --> Completed
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Journal:  Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer. (Pubmed Central) -  May 24, 2019   
    There are no available published data regarding the combination of ribociclib and palliative RT. We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University (Florence, Italy) giving palliative RT concomitant to ribociclib plus letrozole as first-line treatment for MBC.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients (clinicaltrials.gov) -  May 24, 2019   
    P=N/A,  N=90, Recruiting, 
    We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University (Florence, Italy) giving palliative RT concomitant to ribociclib plus letrozole as first-line treatment for MBC. Trial completion date: Mar 2019 --> Mar 2022 | Trial primary completion date: Mar 2018 --> Mar 2021
  • ||||||||||  letrozole / Generic mfg., everolimus / Generic mfg.
    Trial completion date, Metastases:  PerELISA: Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (clinicaltrials.gov) -  May 17, 2019   
    P1,  N=42, Active, not recruiting, 
    Trial completion date: Sep 2019 --> Jul 2019 | Trial primary completion date: Sep 2019 --> Jul 2019 Trial completion date: Jul 2020 --> Jul 2019
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Review, Journal:  Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. (Pubmed Central) -  May 15, 2019   
    Avitinib, olmutinib, and pelitinib are additional type VI inhibitors in clinical trials for non-small cell lung cancer that target EGFR. Secondary resistance to both targeted and cytotoxic drugs is the norm, and devising and implementing strategies for minimizing or overcoming resistance is an important goal in cancer therapeutics.
  • ||||||||||  letrozole / Generic mfg., everolimus / Generic mfg.
    Enrollment closed, Trial completion date, Metastases:  PerELISA: Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (clinicaltrials.gov) -  May 14, 2019   
    P1,  N=42, Active, not recruiting, 
    Trial completion date: Feb 2020 --> Sep 2020 | Trial primary completion date: Feb 2020 --> Sep 2020 Recruiting --> Active, not recruiting | Trial completion date: Jul 2019 --> Jul 2020
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Clinical, Journal:  Pharmacological profile and clinical findings of palbociclib (IBRANCE capsule 25 mg/125 mg) (Pubmed Central) -  May 7, 2019   
    In the PALOMA-3 study, the combination of palbociclib and fulvestrant was associated with significant improvements in PFS compared with fulvestrant plus placebo in patients with metastatic breast cancer. The rate of dose reduction or interruption of dosing by adverse events is higher in palbociclib group compared with placebo group in both studies while the rate of discontinuation of treatment was comparable.
  • ||||||||||  Journal:  Comprehensive Genomic Profiling Aids in Treatment of a Metastatic Endometrial Cancer. (Pubmed Central) -  May 2, 2019   
    Additionally, clinical benefit from an mTOR inhibitor may reflect a response to targeting the alteration in PIK3CA or TSC2 . More research is needed to understand the activity of FGFR3-TACC3 fusions on tumors and to discover additional therapeutic options for endometrial carcinoma patients with this gene fusion.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment open, Trial primary completion date, Metastases:  Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) -  May 2, 2019   
    P2,  N=55, Recruiting, 
    More research is needed to understand the activity of FGFR3-TACC3 fusions on tumors and to discover additional therapeutic options for endometrial carcinoma patients with this gene fusion. Active, not recruiting --> Recruiting | Trial primary completion date: Mar 2019 --> Aug 2019
  • ||||||||||  letrozole / generics
    Clinical, Journal, Monotherapy:  Letrozole Monotherapy in Pre- and Early-Pubertal Boys Does Not Increase Adult Height. (Pubmed Central) -  Apr 27, 2019   
    The Lz-treated boys had similar adult heights with the subjects who received Pl for 2 years, which indicates that the treatment is not beneficial when given to pre- or early-pubertal boys. Previously observed vertebral deformities ameliorated during follow-up, which supports the skeletal safety of Lz therapy in children and adolescents.